FREE DOWNLOAD: 5 Stocks To Buy & Hold Forever
New research report reveals the top 5 stocks to buy & HOLD FOREVER...

...through every wild market swing and through every unknown economic shift in the future.

(It's a quick read.)
Click to download.
Kenneth C. Frazier, insider at Merck & Co., Inc.
Kenneth C. Frazier Insider Alerts

Get notified the next time Kenneth C. Frazier buys or sells Merck & Co., Inc. stock. Enter your email address below to get our daily insider buying and selling report.

Kenneth C. Frazier Insider Information

Insider of Merck & Co., Inc.
Kenneth C. Frazier is the Executive Chairman of Merck’s board of directors, a role he began in July 2021, following his retirement from a decade-long tenure as Merck’s President and Chief Executive Officer.   

Under Ken’s leadership, Merck delivered innovative life-saving medicines and vaccines as well as long-term and sustainable value to its multiple stakeholders.  Ken substantially increased Merck’s investment in research, including early research, while refocusing the organization on the launch and growth of key products that provide far-reaching benefits to society.  He also led the formation of philanthropic and humanitarian initiatives that build on Merck’s 130-year legacy.

Ken joined the company in 1992 and held positions of increasing responsibility, including General Counsel, before becoming President and CEO in 2011.  Prior to joining Merck, Ken was a Partner with the Philadelphia law firm of Drinker Biddle & Reath.  Ken’s contributions, especially in the legal, business, and humanitarian fields, have been widely recognized.  He sits on the boards of Weill Cornell Medicine, Exxon Mobil Corporation, the National Constitution Center and Cornerstone Christian Academy in Philadelphia, PA.  He is Co-Founder and Co-Chair of OneTen, a coalition of leading organizations committed to upskilling, hiring, and promoting one million Black Americans into family-sustaining jobs.  OneTen is committed to facilitating a meaningful, measurable, and lasting impact on racial and economic justice.  Ken is also Chairman, Health Assurance Initiatives, at the venture capital firm, General Catalyst, where he advises on investments and partnerships and provides mentorship to founders building companies that are well positioned to transform the healthcare industry through collaborative and responsible innovation.  He also is a member of the American Academy of Arts and Sciences, the American Philosophical Society, The Business Council, the Council of the American Law Institute, the American Bar Association, and a Fellow of the College of Physicians of Philadelphia.  Additionally, Ken is Co-Chair of the Legal Services Corporation’s Leaders Council.

As a strong advocate for social justice and economic inclusion, Ken is the recipient of numerous awards and honors, including the Anti-Defamation League Courage Against Hate Award, the Botwinick Prize in Business Ethics from Columbia Business School, the Legend in Leadership Award from the Yale School of Management, the NAACP Legal Defense and Educational Fund National Equal Justice Award, and the National Minority Quality Forum’s Lifetime Achievement Award.  In 2018, Ken received the Harvard Law School Association Award, the highest honor given by the prestigious association, in recognition of his extraordinary service to the legal profession, Harvard Law School, and the public. In that same year, Ken was named one of the World’s Greatest Leaders by Fortune magazine and was also named one of TIME’s 100 Most Influential People and again made that list in 2021.  In 2019, he became the first recipient of the Forbes Lifetime Achievement Award for Healthcare.  In 2021, Columbia Business School honored him with the Deming Cup for Operational Excellence, and his peers named Ken Chief Executive magazine’s CEO of the Year.

Ken received his bachelor’s degree from The Pennsylvania State University and holds a J.D. from Harvard Law School.

What is Kenneth C. Frazier's net worth?

The estimated net worth of Kenneth C. Frazier is at least $80.51 million as of March 20th, 2019. Mr. Frazier owns 990,451 shares of Merck & Co., Inc. stock worth more than $80,513,762 as of January 20th. This net worth evaluation does not reflect any other assets that Mr. Frazier may own. Learn More.

What is Kenneth C. Frazier's salary?

As the Insider of Merck & Co., Inc., Mr. Frazier earned a total compensation package of $22,088,429.00 in 2020. Mr. Frazier earned a salary of $1,702,006.00, stock awards of $10,778,499.00, options awards of $4,724,098.00, non-equity compensation of $2,218,500.00, and other compensation of $376,685.00.

How do I contact Kenneth C. Frazier?

The corporate mailing address for Mr. Frazier and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]

Has Kenneth C. Frazier been buying or selling shares of Merck & Co., Inc.?

Kenneth C. Frazier has not been actively trading shares of Merck & Co., Inc. during the last quarter. Most recently, Kenneth C. Frazier sold 663,881 shares of the business's stock in a transaction on Tuesday, November 9th. The shares were sold at an average price of $82.26, for a transaction totalling $54,610,851.06.

Who are Merck & Co., Inc.'s active insiders?

Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Rita Karachun (VP), and Caroline Litchfield (CFO).

Are insiders buying or selling shares of Merck & Co., Inc.?

During the last year, insiders at the sold shares 8 times. They sold a total of 956,108 shares worth more than $80,196,014.36. The most recent insider tranaction occured on November, 9th when insider Kenneth C Frazier sold 663,881 shares worth more than $54,610,851.06. Insiders at Merck & Co., Inc. own 0.3 % of the company.

Information on this page was last updated on 11/9/2021.

Kenneth C. Frazier Insider Trading History at Merck & Co., Inc.

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/9/2021Sell663,881$82.26$54,610,851.06View SEC Filing Icon  
3/20/2019Sell192,736$82.05$15,813,988.80990,451View SEC Filing Icon  
3/13/2019Sell18,725$82.00$1,535,450.00816,440View SEC Filing Icon  
3/5/2019Sell20,105$82.00$1,648,610.00810,859View SEC Filing Icon  
2/22/2019Sell53,961$80.02$4,317,959.22733,942View SEC Filing Icon  
2/19/2019Sell135,613$80.03$10,853,108.39784,863View SEC Filing Icon  
2/15/2019Sell92,913$80.03$7,435,827.39784,863View SEC Filing Icon  
2/5/2019Sell231,566$78.08$18,080,673.28923,516View SEC Filing Icon  
10/2/2018Sell279,850$72.07$20,168,789.50971,800View SEC Filing Icon  
9/18/2018Sell279,851$70.08$19,611,958.08971,801View SEC Filing Icon  
7/31/2018Sell228,091$65.00$14,825,915.00938,788View SEC Filing Icon  
11/10/2016Sell140,000$65.03$9,104,200.00514,957View SEC Filing Icon  
8/5/2016Sell392,000$61.81$24,229,520.00760,877View SEC Filing Icon  
7/5/2016Sell60,000$58.00$3,480,000.00554,856View SEC Filing Icon  
4/14/2016Sell131,040$56.11$7,352,654.40653,517View SEC Filing Icon  
2/18/2015Sell5,164$58.67$302,971.88View SEC Filing Icon  
1/9/2015Sell8,840$62.47$552,234.80View SEC Filing Icon  
12/10/2014Sell9,846$60.00$590,760.00View SEC Filing Icon  
11/10/2014Sell10,000$57.98$579,800.00View SEC Filing Icon  
10/10/2014Sell9,895$59.73$591,028.35View SEC Filing Icon  
9/10/2014Sell9,814$60.48$593,550.72View SEC Filing Icon  
8/11/2014Sell10,058$57.00$573,306.00View SEC Filing Icon  
7/10/2014Sell9,987$58.03$579,545.61View SEC Filing Icon  
6/10/2014Sell9,985$58.06$579,729.10View SEC Filing Icon  
See Full Table

Kenneth C. Frazier Buying and Selling Activity at Merck & Co., Inc.

This chart shows Kenneth C Frazier's buying and selling at Merck & Co., Inc. by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Merck & Co., Inc. Company Overview

Merck & Co., Inc. logo
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
Read More

Today's Range

Now: $81.29
Low: $80.48
High: $81.98

50 Day Range

MA: $78.16
Low: $72.28
High: $84.11

2 Week Range

Now: $81.29
Low: $70.89
High: $91.40

Volume

11,446,108 shs

Average Volume

12,901,572 shs

Market Capitalization

$205.33 billion

P/E Ratio

28.72

Dividend Yield

3.38%

Beta

0.49
Free Pick from Jeff Brown: “Buy S.C.G .”
Jeff Brown picked Tesla in 2018 before it jumped 1,390%. He picked Nvidia before it jumped 3,545%. And he picked Bitcoin before it skyrocketed 22,750%.

And now he’s saying S.C.G. will be the next big tech play. He’s not the only one. Apple’s CEO even called it “the next big thing.”
Click here and get the name and ticker symbol!